Scholarlink

Aim <p>This review systematically evaluated the impact of enzyme replacement therapy (ERT) on audiological outcomes in Fabry disease, focusing on the nature of audiological findings, therapeutic effects on hearing function, and factors influencing treatment response.</p> Method <p>The systematic review was conducted following PRISMA 2020 guidelines. Literature searches were performed across PubMed, PubMed Central, ScienceDirect, J-Gate, ProQuest, Web of Science, EBSCO, and Google Scholar up to 2025. Reference lists of eligible studies were also manually screened to identify additional relevant publications on audiological outcomes in Fabry disease patients undergoing ERT.</p> Results <p>Ten studies comprising 404 patients were included. Across studies, ERT generally stabilized hearing thresholds, with modest improvements reported in some cases, particularly when therapy was initiated early. Factors such as disease stage and timing of therapy influenced the extent of auditory benefit.</p> Conclusion <p>ERT appears effective in preventing further auditory deterioration in Fabry disease, with potential for modest improvement when initiated early. Evidence is limited by variability in study designs, small sample sizes, and challenges inherent to rare conditions, including difficulties in longitudinally tracking patients across treatment timelines.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of enzyme replacement therapy on hearing sensitivity in Fabry disease: A systematic review

  • 期刊论文

  • 发表日期：

    2025年12月22日

查看全文
  • Sreeraj Konadath,
  • Praveen Prakash,
  • Achu Abraham,
  • Adithya Sreedharan Sanitha,
  • Yerraguntla Krishna,
  • Abdulaziz Almudhi,
  • Irfana Madathodiyil,
  • Reesha Oovattil Hussain

摘要

Aim

This review systematically evaluated the impact of enzyme replacement therapy (ERT) on audiological outcomes in Fabry disease, focusing on the nature of audiological findings, therapeutic effects on hearing function, and factors influencing treatment response.

Method

The systematic review was conducted following PRISMA 2020 guidelines. Literature searches were performed across PubMed, PubMed Central, ScienceDirect, J-Gate, ProQuest, Web of Science, EBSCO, and Google Scholar up to 2025. Reference lists of eligible studies were also manually screened to identify additional relevant publications on audiological outcomes in Fabry disease patients undergoing ERT.

Results

Ten studies comprising 404 patients were included. Across studies, ERT generally stabilized hearing thresholds, with modest improvements reported in some cases, particularly when therapy was initiated early. Factors such as disease stage and timing of therapy influenced the extent of auditory benefit.

Conclusion

ERT appears effective in preventing further auditory deterioration in Fabry disease, with potential for modest improvement when initiated early. Evidence is limited by variability in study designs, small sample sizes, and challenges inherent to rare conditions, including difficulties in longitudinally tracking patients across treatment timelines.